Clinical Studies

CLL Patient

Our CLL patient is a 64-Year-Old male who was diagnosed with CLL (Chronic Lymphocytic Leukemia) in 2021. He was a patient at Mayo Clinic, FL and the conversation around remission stopped when a mutation was found that took his outcome from good to poor. Despite 3-years of targeted therapy, he never achieved remission, with tumor cell infiltration in the bone marrow measuring 20% prior to treatment with NK101. In addition to an elevated B-cell count, the patient suffered with daily body pain, exhaustion, fogginess, and overall discomfort. Patient 1 received a single infusion of approximately 350 million NK101 cells on December 5, 2023, with post-infusion blood work showing a positive early immune response and no adverse safety events. The 90-day review of the post-infusion test results provide early signs of partial remission after only one treatment, with validated data points confirming NK101’s ability to target and spontaneously kill the tumor cells that had infiltrated the bone marrow; reverse disease progression; and restore partial immune function. The early clinical data is consistent with Dr. Jewett's preclinical results.